

# SPHHP Research Activities Newsletter

University at Buffalo

May 2018

## In the News

### Congratulations to the Following Awardees!



**Katarzyna Kordas**, Associate Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Institute of Environmental Health Sciences/NIH for the project entitled, *Low Level Exposure to Multiple Levels: Effects on Cognition and Behavior*. The study will continue to determine how children's exposure to multiple metals affects specific cognitive functions and behavior through middle childhood.



**Jeffrey Miecznikowski**, Associate Professor of Biostatistics, **Ekaterina Noyes**, Professor of Epidemiology and Environmental Health, and **Greg Wilding**, Professor and Chair of Biostatistics, are Co-Is on UB's National Center for Advancing Translational Sciences/NIH continuation award (PI: Timothy Murphy, Medicine) for the project entitled, *Buffalo Clinical and Translational Research Center*. Drs. Miecznikowski, Noyes and Wilding are members of the CTSA's



Biostatistics, Epidemiology and Research Design (BERD) core, which offers a range of educational and training opportunities that are responsive to the needs and schedules of faculty, trainees and research staff.



**Jihnee Yu**, Associate Professor of Biostatistics, is Co-I on a continuation award (PI: Hui Meng, Mechanical and Aerospace Engineering) from the National Institute of Neurological Disorders and Stroke/NIH for the project entitled, *Virtual Intervention of Intracranial Aneurysms*. The study will continue to develop a method of predicting treatment outcome of intracranial aneurysms with clinically-practical computational tools to simulate endovascular treatment strategies. It also will create predictive models that utilize hemodynamics from computational fluid dynamics (CFD) simulations on cases treated *in silico*.



**Jean Wactawski-Wende**, Dean of SPHHP and SUNY Distinguished Professor of Epidemiology and Environmental Health, is Co-Investigator on a continuation award (PI: Yijun Sun, Microbiology and Immunology) from the National Institute of General Medical Sciences/NIH for the project entitled, *Developing Advanced Algorithms to Address Major Computational Challenges in Current Microbiome Research*. The project will continue to develop a novel analytical strategy to significantly advance the understanding of dynamic behaviors of oral microbial communities possibly contributing to the development of periodontal disease.



**James Sackett**, Predoctoral Student in Exercise and Nutrition Sciences, received a fellowship from the American College of Sports Medicine for the project entitled, *Ventilatory Control during Simulated Weightlessness*. The study will investigate the underlying physiology of CO<sub>2</sub> retention during simulated microgravity. The findings will be instrumental to conducting further research that focuses on the underlying mechanisms of CO<sub>2</sub> retention and the development of interventions of CO<sub>2</sub> retention during space flight. **Blair Johnson**, Assistant Professor of Exercise and Nutrition Sciences, is Faculty Sponsor.

#### Inside this issue:

In the News	1
Grant Clinic	2
NIH Funding:	
Limited	2-3
RFA	3-7
PAR	7-8
PA	8-9
PostDoc Fellow	9
Foundations:	
Robert Wood Johnson	9
Words to Live By	9

## Grant Clinic

### [NOT-OD-18-179](#)

#### **Transition from Inclusion Management System to New Human Subjects System (HSS) as of June 9, 2018**

NIH has developed a new Human Subjects System, which consolidates human subjects and clinical trial information in one place. Information captured in HSS is generally submitted on the PHS Human Subjects and Clinical Trials Information form in application packages submitted for due dates January 25, 2018 or later and Research Progress Performance Reports (RPPR). HSS will replace the Inclusion Management System (IMS), used for reporting participant sex/gender, race, and ethnicity information. The Inclusion link will no longer appear on the Commons Status page as of **June 9, 2018**. For additional information on the key changes, please refer to the NIH Notice.

### [NOT-OD-18-175](#)

#### **Ruth L. Kirschstein National Research Service Award (NRSA) Stipends, Tuition/Fees and Other Budgetary Levels Effective for Fiscal Year 2018**

NIH has posted updated stipend levels effective for the FY 2018. Both predoctoral and postdoctoral stipends have increased, as well as the training related expenses and institutional allowances for postdoctoral trainees and fellows. The stipend for predoctoral students is \$24,324. Please see the Notice for the postdoctoral stipend levels and amounts.

### [NOT-CA-18-063](#)

#### **National Cancer Institute Request for Information (RFI): Strategies for Matching Patients to Clinical Trials**

NCI seeks public comments on approaches to improve the ease and functionality of searching for cancer clinical trials. These approaches can focus on how to find a cancer clinical trial to participate in, or finding participants for clinical trials. Please refer to the NIH Notice for specific areas of focus. Comments and relevant citations on any of the above outlined areas should be submitted electronically to [FindingCancerTrialsCollaborative@mail.nih.gov](mailto:FindingCancerTrialsCollaborative@mail.nih.gov), or mailed to: Coordinating Center for Clinical Trials (CCCT) 6W610, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20890.

### [NOT-AG-18-013](#)

#### **Notice of Pre-Submission Webinars for PAR-18-749 "Examining Diversity, Recruitment and Retention in Aging Research (R24, clinical trial not allowed)"**

NIA will hold pre-application technical webinars to review the purpose and objectives of the FOA. If interested, applicants should register by sending an email to [HDRPN@mail.nih.gov](mailto:HDRPN@mail.nih.gov), indicating "Recruitment R24 Webinar Registration" in the subject line, at least one week prior to the meeting date. Applicants are also encouraged to submit questions prior to the webinars at the same email, indicating "Recruitment R24 Webinar" in the subject line. The dates and times of the webinars are:

Tuesday, June 12, 2018 from 10:00AM - 11:00 AM (Eastern Standard Time)

Tuesday, August 14, 2018 from 10:00AM - 11:00 AM (Eastern Standard Time)

Tuesday, December 11, 2018 from 10:00AM - 11:00 AM (Eastern Standard Time)

Potential applicants are strongly encouraged to submit questions prior to the webinars to the email address above.

### [NOT-TR-18-024](#)

#### **Notice of Change of Application Due Date to PAR-18-245 "Limited Competition: Exploratory CTSA Collaborative Innovation Awards (R21)"**

The expiration date for PAR-18-245 has been extended to November 30, 2018 (previously July 31, 2018). This allows for an additional submission cycle with a due date of November 29, 2018 in addition to the July 30, 2018 due date.

## NIH Funding Opportunities: **Limited Submissions**

UB prior approval is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mail-box](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramosch on behalf of the OVPRED. He may be contacted at [kmt1@buffalo.edu](mailto:kmt1@buffalo.edu) or by phone at 645-3321 for any questions or advice about the limited submission process.

### [PAR-17-340 \(RM1\) – \(clinical trial not allowed\)](#)

#### **Collaborative Program Grant for Multidisciplinary Teams**

This FOA is designed to support highly integrated research teams of three to six PD/PIs to address research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields. *Only one application per institution per review cycle is allowed.* **Application Due Dates:** September 7, 2018; May 7, 2019; September 7, 2019; May 7, 2020; September 7, 2020

[RFA-RM-18-810 \(DP5\)](#) – clinical trial optional

**NIH Director's Early Independence Award**

This award supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. *Only two applications per institution are allowed.* **Application Due Date:** September 27, 2018

## NIH Funding Opportunities: Requests for Applications (RFA)

### July Due Dates

[RFA-AG-19-002 \(R03\)](#) – clinical trial optional; [RFA-AG-19-003 \(R03\)](#) – clinical trial not allowed

**Small Research Grant Program for the Next Generation of Researchers in Alzheimer's Disease (AD) and Alzheimers Disease Related Dementias (ADRD) Research**

These programs seek (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, AD/ADRD and healthy brain aging, and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new innovative AD/ADRD research programs that leverage and build upon their existing expertise. **Application Due Date:** July 3, 2018

[RFA-RM-18-011 \(U01\)](#) – clinical trial not allowed

**Cutting Edge Informatics Tools for Illuminating the Druggable Genome (IDG)**

This FOA is a part of the Implementation Phase of the NIH Common Fund program, Illuminating the Druggable Genome (IDG) <https://pharos.nih.gov/idg/index>. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. **Application Due Date:** July 9, 2018

[RFA-DK-17-027 \(R01\)](#) – clinical trial required

**Incorporating Patient-Reported Outcomes into Clinical Care for Type 1 Diabetes**

This FOA will support research to test approaches in the healthcare setting to using Patient-Reported Outcomes (PROs) as tools to enhance patient-centered treatment and improve outcomes in individuals with type 1 diabetes.

**Application Due Date:** July 10, 2018

[RFA-DK-17-028 \(R01\)](#) – clinical trial required

**Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes**

This FOA seeks applications for clinical trials testing interventions targeting diabetes distress in individuals with T1D and/or their caregivers, with the goal of understanding whether lowering diabetes distress will improve glycemic control and quality of life. **Application Due Date:** July 10, 2018

[RFA-NS-18-032 \(R35\)](#) – clinical trial optional

**Research Program Award – National Institute of Neurological Disorders and Stroke**

This award provides longer-term support and increased flexibility to PIs whose records of research achievement demonstrate their ability to make major contributions to neuroscience. The award will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support. **Application Due Date:** July 13, 2018

[RFA-AI-18-017 \(R01\)](#) – clinical trial not allowed

**Next-Generation Biologics for Sustained HIV Remission**

The objective of this FOA is to develop next-generation biologics that have the potential to achieve sustained viral remission in HIV-infected individuals as an alternative to life-long cART. The proposed biologic(s) should be rationally designed or chosen, must not have been employed in the HIV field before, and should leverage the newest immuno-pharmacological technologies and platforms. **Application Due Date:** July 27, 2018

[RFA-ES-18-006 \(R43/R44\)](#) – clinical trial not allowed

**SBIR E-learning for HAZMAT and Emergency Response**

This FOA encourages applications from small business concerns that propose to further the development of Advanced Technology Training (ATT) products for: the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biosafety response, infectious disease training and cleanup; emergency responders in disasters and resiliency training; and for ATT tools to assist in research into the acute and long-term health effects of environmental disasters.

**Application Due Date:** July 31, 2018

## August Due Dates

[RFA-CA-18-011 \(R44\)](#) – clinical trial optional

### **SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization**

This FOA solicits applications from small business concerns that seek additional funding to support the next stage of development for cancer-relevant projects that were previously funded under SBIR or STTR Phase II awards from any Federal agency. **Application Due Date:** August 15, 2018

[RFA-DA-18-022 \(R01\)](#) – clinical trial optional

### **Advancing Exceptional Research on HIV/AIDS and Substance Abuse**

This FOA focuses on innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention and treatment of HIV/AIDS among substance abusers. The nexus with drug abuse should be clearly described. This FOA is open to both individual researchers and research teams and is not limited to any one area of research on HIV and substance use, but all studies must focus on NIH HIV/AIDS Research Priorities <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>.

**Application Due Date:** August 22, 2018

## September Due Dates

[RFA-RM-18-007 \(DP1\)](#) – clinical trial optional

### **NIH Director's Pioneer Award**

This award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative approaches to major challenges in the biomedical or behavioral sciences towards the goal of enhancing human health. Applications from individuals with diverse backgrounds and in any topic relevant to the broad mission of NIH are welcome. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere.

**Application Due Date:** September 14, 2018

[RFA-CA-18-026 \(R01\)](#) – clinical trial required

### **Improving the Reach and Quality of Cancer Care in Rural Populations**

The FOA encourages two types of applications: 1) observational research that includes pilot testing of intervention to understand and address predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations; or 2) intervention research to address known predictors of cancer care/treatment and outcomes in rural low-income and/or underserved populations. **Application Due Date:** September 19, 2018

[RFA-CA-18-004 \(R21\)](#) – clinical trial not allowed

### **Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. **Application Due Dates:** September 28, 2018

[RFA-CA-18-005 \(R33\)](#) – clinical trial not allowed

### **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. **Application Due Dates:** September 28, 2018

## October Due Dates

[RFA-MH-17-604 \(R61/R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

[RFA-MH-17-606 \(R33\)](#) - **Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

The purpose of these FOAs is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. These FOAs support the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. **Application Due Dates:** October 15, 2018

[RFA-MH-17-612 \(R34\)](#)

**Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions**

This FOA encourages pilot research consistent with [NIMH's priorities](#) for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. **Application Due Dates:** October 15, 2018

[RFA-MH-18-700 \(Collaborative R01\)](#) - clinical trial and participation of two or more collaborative sites required

[RFA-MH-18-701 \(R01\)](#) – clinical trial required

**Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions**

These FOA support clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings.

**Application Due Dates:** October 15, 2018

[RFA-MH-18-702 \(R61/R33\)](#) – clinical trial required

[RFA-MH-18-703 \(R33\)](#) - clinical trial required

**Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders**

These FOAs support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

**Application Due Dates:** October 15, 2018

[RFA-MH-18-704 \(R61/R33\)](#) – clinical trial required

[RFA-MH-18-705 \(R33\)](#) – clinical trial required

**Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders**

These FOAs support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach.

**Application Due Dates:** October 15, 2018

[RFA-MH-18-707 \(R01\)](#) – clinical trial required

**Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders**

This FOA supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention.

**Application Due Dates:** October 15, 2018

[RFA-CA-18-019 \(R01\)](#); [RFA-CA-18-020 \(R21\)](#) - clinical trial optional

**Research Answers to NCI's Provocative Questions**

The purpose of these FOAs are to support research projects designed to solve specific problems and paradoxes in cancer research identified by the NCI Provocative Questions initiative. Each research project must be focused on addressing one particular research problem defined by one specific PQ selected from the list found in the FOAs.

**Application Due Dates:** October 30, 2018

[RFA-CA-18-021 \(R01\)](#); [RFA-CA-18-022 \(U01\)](#); [RFA-CA-18-023 \(P01\)](#); [RFA-CA-18-024 \(P50\)](#) – clinical trial optional

**Revision Applications to National Cancer Institute (NCI)-supported Awards to Include Research on the NCIs Provocative Questions**

These FOAs invite revision applications from investigators with active NCI R01, U01, P01 or P50 research grants and are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent award.

**Application Due Dates:** October 30, 2018

**November Due Dates**

[RFA-DA-19-005 \(R61/R33\)](#) – clinical trial required

**Science-Based Quality Measurement and Management Development for Opioid Use Disorder Treatment**

This FOA solicits applications proposing phased research projects, with transition milestones, to develop and rigorously test the effects of strategies to improve opioid treatment quality measures, both on changes in the measures themselves and on patient outcomes. The overall goal is to advance the field of clinical quality measurement and management in opioid use disorder treatment by generating research better aligning quality measurement with quality improvement.

**Application Due Date:** November 7, 2018

## December Due Dates

[RFA-DK-17-024 \(R01\)](#) – clinical trial required

### **Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D)**

This FOA encourages clinical trials testing the clinical efficacy of new technology to improve glucose control, reduce hypoglycemic events and/or improve quality of life in older T1D patients (aged 65 and older). Studies may utilize CGM technologies in open or closed loop systems with different degrees of automation (sensor/MDI, sensor augmented pumps with or without low glucose suspend (LGS), hybrid and fully automated systems).

**Application Due Dates:** December 6, 2018

[RFA-DK-18-002 \(R01\)](#) – clinical trial optional

### **Understanding Skeletal Effects of Type 1 Diabetes**

This FOA invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.

**Application Due Date:** December 6, 2018

## Multiple Due Dates

[RFA-HL-19-027 \(U34\)](#) – clinical trial not allowed

### **Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans**

This FOA provides support for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. The FOA will support the development of feasible and well-designed clinical trials utilizing consultative services provided by the Innovative Clinical Trials Resource (ICTR) (N01).

**Application Due Dates:** July 19, 2018; October 19, 2018

[RFA-HL-19-023 \(T32\)](#) – clinical trial not allowed

### **T32 Training Program for Institutions That Promote Diversity**

The NHLBI's T32 Training Program is intended to support training of predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, or institutions that have been identified by federal legislation as having an institutional mission focused on these populations, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders. **Application Due Dates:** September 4, 2018; February 26, 2019; September 4, 2019; February 26, 2020; September 4, 2020; February 26, 2021

[RFA-HL-19-016 \(R43\)](#) – clinical trial not allowed

### **Technologies for Healthy Independent Living for Heart, Lung, Blood and Sleep Disorders**

This FOA seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. **Application Due Dates:** September 10, 2018; June 10, 2019; June 10, 2020

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

### **Short-Term Research Education Program to Increase Diversity in Health-Related Research**

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. This FOA will support creative educational activities with a primary focus on Research Experiences. **Application Due Dates:** September 10, 2018, February 26, 2019, September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021

[RFA-OD-18-002 \(R01\)](#); [RFA-OD-18-003 \(R21\)](#); [RFA-OD-18-001 \(R03\)](#) – clinical trial optional

### **Tobacco Regulatory Science**

The purpose of these FOAs is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration Center for Tobacco Products (CTP). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

**Application Due Dates:** July 17, 2018, February 13, 2019

[RFA-OD-18-001 \(R03\)](#) – clinical trial optional

**Tobacco Regulatory Science Small Grant Program for New Investigators**

The purpose of this FOA is to invite applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Only [New Investigators](#) who fit the criteria are eligible to apply. **Application Due Dates:** July 17, 2018, February 13, 2019

[RFA-HL-17-022 \(R21\)](#)

**Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research**

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Dates:** October 17, 2018; February 15, 2019; October 17, 2019

[RFA-DA-18-020 \(UG3/UH3\)](#) – clinical trial optional

**NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders**

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. **Application Due Dates:** July 25, 2018; July 25, 2019, July 25, 2020

[RFA-DA-18-019 \(DP1\)](#) – clinical trial optional

**NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research**

This Program supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities. **Application Due Dates:** August 14, 2018; August 14, 2019; August 14, 2020

[RFA-ES-16-005 \(R21\)](#)

**Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA is intended to support environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data to understand the consequences of natural and man-made disasters or emerging environmental public health threats in the U.S. and abroad. A distinguishing feature of an appropriate study is a shortened timeframe from submission to award. The entire cycle is expected to be within 3-4 months. **Application Due Dates:** Multiple due dates, please see FOA. **Expiration Date:** June 2, 2019

[RFA-DA-19-002 \(UG3/UH3\)](#) – clinical trials optional

**Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose**

Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose.

**Application Due Dates:** Applications will be accepted on a rolling basis, beginning on January 25, 2018

**Expiration Date:** January 2, 2020

**NIH Funding Opportunities: Program Announcement Reviewed by an Institute (PAR)**

[PAR-18-747 \(R01\)](#); [PAR-18-745 \(R21\)](#) – clinical trial optional

**Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S.**

These FOAs support multidisciplinary research projects that examine the following: sociodemographic, cultural, economic, epidemiologic, and biological factors in opioid care specific to health disparity populations that increase the risk of OUD; the consequences of OUD; ways to improve resource availability among defined health disparity populations to reduce opioid treatment gap; and underlying mechanisms for the variation in the prevalence of OUD in health disparities populations. Research projects are encouraged to utilize rigorous innovative multi multidisciplinary approaches with integration of multiple factors that are known to be related to opioid health disparities.

**Application Due Dates:** June 14, 2018, November 14, 2018, June 14, 2019, November 14, 2019, June 15, 2020 and November 13, 2020

[PAR-18-768 \(X01\)](#) – clinical trial not allowed

**Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans Resource Access**

The purpose of this FOA is to provide access to a consultative resource for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute (NHLBI) and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. **Application Due Dates:** July 19, 2018; October 19, 2018

[PAR-18-777 \(R01\)](#); [PAR-18-778 \(R21\)](#); [PAR-18-779 \(R43/R44\)](#) – clinical trial not allowed

**Novel Genomic Technology Development**

These FOAs seek grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

**Application Due Dates:** October 2, 2018; October 2, 2019; October 2, 2020

[PAR-18-767 \(Collaborative U54\)](#) – clinical trial optional

**Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE)**

The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSS) and NCI-designated Cancer Centers (CCs). The institutions in each partnership are expected to work collaboratively to:

1) increase the cancer research and cancer research education capacity of the ISUPSS; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities. **Application Due Dates:** January 9, 2019; January 9, 2020

[PAR-18-749 \(R24\)](#) – clinical trial not allowed

**Examining Diversity, Recruitment and Retention in Aging Research**

This initiative will foster a collaborative network of teams to engage large diverse populations and accelerate research participant recruitment into aging research and NIA funded clinical studies. Collaboratory teams will support the creation of a portfolio of timely and essential enabling resources designed to enhance the recruitment and retention of a large diverse community population for aging research. The teams will be required to implement these resources either in a regional (community of greater than 20,000) or national scope (more than one geographic area) by organizing numerous local activities as part of the assembled team. **Application Due Dates:** Standard dates apply;

**Expiration Date:** January 26, 2021

[PAR-18-764 \(R01\)](#) – clinical trial optional

**Harnessing Big Data to Halt HIV**

This FOA will support projects to assemble diverse big data sources, conduct robust and reproducible analyses, and create meaningful visualizations of big data, as well as, engage ethical experts where appropriate to ensure the development of this scientific area is guided by ethical principles. **Application Due Date:** Standard AIDS dates apply;

**Expiration Date:** May 8, 2021

[PAR-18-769 \(R01\)](#)

**NIOSH Occupational Safety and Health Research**

The purpose of this grant program is (1) to develop an understanding of the risks and conditions associated with occupational diseases and injuries, (2) to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and (3) to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. **Application Due Dates:** July 6, 2018 for new, August 6, 2018 for resubmission, renewal and revision applications, then standard due dates;

**Expiration Date:** November 18, 2023

## NIH Funding Opportunities: Program Announcements (PA)

The following program announcements have standard due dates, unless otherwise noted.

[PA-18-750 \(R18\)](#)

**Making Health Care Safer in Ambulatory Care Settings and Long Term Care Facilities**

Expiration Date: September 8, 2021

[PA-18-753 \(R01\)](#) – clinical trials optional

[PA-18-754 \(R21\)](#) – clinical trials not allowed

**Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity**

Expiration Date: May 8, 2021



[PA-18-773 \(R01\)](#) – clinical trial optional  
**International Research Collaboration on Drug Abuse and Addiction Research**  
Expiration Date: May 8, 2021

[PA-18-774 \(R34\)](#) – clinical trial optional  
**Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders**  
Expiration Date: May 8, 2021

[PA-18-775 \(R34\)](#) – clinical trial optional  
**Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials**  
Expiration Date: January 8, 2021

[PA-18-776 \(R01\)](#) – clinical trial optional  
**Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children**  
Expiration Date: September 8, 2021

[PA-18-780 \(R34\)](#) – clinical trial optional  
**Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation**  
Expiration Date: May 8, 2021

#### Specific Due Dates:

[PA-18-748 \(Admin Supp\)](#) – clinical trial not allowed  
**Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies**  
Application Due Date: July 1, 2018

[PA-18-751 \(Admin Supp.\)](#) – clinical trial not allowed  
**Geriatrics and Clinical Gerontology Research to Address Health Disparities in the U.S.**  
Application Due Date: July 16, 2018

[PA-18-765 \(R36\)](#)  
**AHRQ Health Services Research Dissertation Program**  
Application Due Dates: February 1, May 1, August 1, and November 1 annually, beginning August 1, 2018  
Expiration Date: May 2, 2023

## NIH Funding Opportunities for Post-Doctoral Fellows

[National Cancer Institute Cancer Prevention Fellowship Program](#), a multidisciplinary program that trains future leaders in the field of cancer prevention and control, is accepting applications for the class entering in June 2019. Applicants must hold a PhD, MD or other doctoral degree in a related discipline and have less than 5 years of relevant postdoctoral experience at time of appointment. Applicants currently enrolled in accredited doctoral degree programs that have not yet fulfilled all degree requirements will be considered for entry into the program, provided that all requirements will be completed before the start of the fellowship. For additional information, please visit CFPF's website, which contains testimonials as well as informational videos on the program. **Application Due Date:** August 25, 2018

## Funding Opportunities: Foundations

### Robert Wood Johnson Foundation

[Policies for Action: Policy and Law Research to Build a Culture of Health](#) is seeking proposals that will investigate public and private policies from a range of political ideologies and perspectives. The [Policies for Action program](#) was created to help build the evidence base for policies that can help build a culture of health. Policies include not only laws and regulations at the local, state, and federal level, but also private sector practices, such as those affecting workplaces, neighborhood and community development, and family stability. These policies and practices might be related to: health care; public health; education and training; housing and community development; civil rights; transportation and planning; labor and employment; taxes and spending. Total award is up to \$250,000 for a maximum of two years.

## Congratulations to our Graduates!!!



*“A diamond is merely a lump of coal that did well under pressure”*

Henry Alfred Kissinger (1923 - )  
Political Scientist, Diplomat and US.  
Secretary of State and National Security  
Advisor under Richard Nixon and Gerald  
Ford